Recipharm is Commencing Negotiations with LIDDS
News Apr 24, 2015
Recipharm has announced that it has commenced negotiations with the pharmaceutical company LIDDS regarding collaboration on manufacture of Liproca Depot® ahead of continued clinical development and a potential future market launch.
In a joint letter of intent the companies have explained their intention to initiate collaboration regarding scale-up, manufacture and quality assurance of LIDDS’ pharmaceutical products. Such a collaboration will initially focus on Liproca® Depot, a targeted treatment for prostate cancer that is currently in Phase II, but it may also include other products based on LIDDS’ unique technology platform. The letter of intent follows a so-called feasibility study performed by Recipharm. The results of this study confirm the possibility of developing a process for manufacture that ensures a high-quality end product.
“Collaboration with a manufacturing partner as renowned as Recipharm increases the power of attraction of our prostate-cancer product Liproca® Depot. A high-quality and cost-effective manufacturing process increases the chances of in the future being able to offer better treatment to patients with prostate cancer,” says Monica Wallter, LIDDS’ CEO.
“There is great potential in LIDDS’ technology platform for development of new treatments for diseases where local administration is desirable. We look forward to contributing with our technical expertise in the field of manufacture, so that cancer patients can in future be offered treatments associated with fewer side effects,” says Maria Lundberg General Manager Recipharm Pharmaceutical Development.
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu VaccineNews
Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018